Načítá se...

Outcomes of patients with CLL treated with first line idelalisib plus rituximab after cessation of treatment for toxicity

BACKGROUND: More active therapies are needed for older and unfit patients with CLL who are not eligible for chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab. The PI3Kδ inhibitor idelalisib is effective in treatment-naïve and relapsed/refractory patients with CLL as monotherapy and...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Cancer
Hlavní autoři:	Thompson, Philip A, Stingo, Francesco, Keating, Michael J, Ferrajoli, Alessandra, Burger, Jan A., Wierda, William G, Kadia, Tapan M, O’Brien, Susan M.
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	2016
Témata:	Article
On-line přístup:	https://ncbi.nlm.nih.gov/pmc/articles/PMC5980238/ https://ncbi.nlm.nih.gov/pubmed/27182988 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30069
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo otaguje tento záznam!

Outcomes of patients with CLL treated with first line idelalisib plus rituximab after cessation of treatment for toxicity

Podobné jednotky